DCAT Summit at Lugano > Speakers
DCAT Sustainability Summit at Lugano Speakers
Nick Hutchinson
Just – Evotec Biologics
Head of Market Development and Sustainability Champion
Olivier Roland
MSD
AVP, Energy, Environmental Sustainability & Integrated Logistics Procurement
Nicole Schumacher
F. Hoffmann-La Roche Ltd
Global Procurement, Team Lead Sustainability & Compliance
Annette Quincy, EcoVadis
Annette Quincy is Global Director of Sector Initiatives at EcoVadis. With 30 years of experience in multiple industries from pharma, packaging, retail, electronics and more, Annette has been a leader in roles from marketing & sales to transformation projects to procurement to technology deployment. She leads strategy and execution of EcoVadis‘ approach to cross-sector collaboration, and is responsible for oversight of 12 Sector Initiatives and the creation & incubation of new ones. She believes that collaboration amongst companies and their ecosystems holds the key to unlock actionable, scalable and magnified impact for the planet and society. A visionary who always dreams big, with mastery in connecting the dots, Annette is an international citizen having lived in multiple countries and currently residing in France.
Arne Kloke, Alliance to Zero
Arne Kloke is the President of the Alliance to Zero, a pharma supply chain initiative that aims to facilitate the transition of injection devices to net-zero. He also serves as Head of Service and Sustainability Management at SCHOTT Pharma, where he is responsible for the company’s sustainability strategy and action program. Within both organizations, his specific interest is working towards product solutions and service models enabling a simultaneous match of environmental responsibility and financial viability. He is a scientist by training, member of the PDA Parenteral Packaging Conference Committee and well experienced in realizing new primary packaging and processing solutions with partners throughout the injectables industry.
Donal Kelleher, MSD
Donal is the Executive Director of External Manufacturing at MSD, leading the External Manufacturing Sustainability Team for MSD with particular focus on Scope 3 Emissions. He had been with MSD for over 20 years and was previously the Engineering Director at MSD Brinny, charged with leading Energy Reduction Program/Resource Reduction for the site. Donal holds a BEng in Chemical Engineering, and a Chartered Engineer (CEng) and a Project Management Professional (PMP).
Olivier Roland, MSD
Olivier is the Associate Vice President of Energy, Environmental Sustainability and Integrated Logistics Procurement at MSD. He has spent 20 years with MSD, and previously led the Canada, EMEA, EEMEA and Integrated Logistics Procurement & Sourcing Organization. Prior to joining MSD, Olivier worked with Accenture and Total Oil and holds a BBA and Masters in Supply Chain Management.
Christian Seufert, Lonza
Christian Seufert is the President of Capsules and Health Ingredients Division at Lonza. Prior too this role, Christian previously spent 20 years at BASF across multiple territories and businesses, most recently as the Senior Vice President for the Pharma Solutions, Nutrition & Health segment where he was responsible for driving operational efficiencies and delivery strategy for organic and inorganic growth.
Dora Rio, SHL Medical
Dora Rio is Head of Sustainability at SHL Medical, where she is responsible for leading the company’s aspiration to bring positive societal impact. Dora has over 20 years of experience in sustainability across healthcare, medtech, research and consultancy. She leads the sustainability strategy and sustainability efforts for SHL Medical, globally. Dora provides thought leadership on global ESG policies and practices, namely environmental sustainability. She holds an MBA in Sustainability Management and an MSc in Environmental Engineering.
Dr. Waldo Mossi, HAS Healthcare Advanced Synthesis
Dr. Waldo Mossi received his PhD & degree in Chemistry at Swiss Federal Institute of Technology in Zurich (ETH). In 1994 he began his career at Helsinn Advanced Synthesis SA as a R&D Responsible. From 2001 to 2013 he held several positions within the Company, such as Director of the Scientific Division and Director of Business Development. From April 2014 to 2021, he was General Manager of Helsinn Advanced Synthesis. Since January 2022, Dr. Mossi is the CEO of HAS Healthcare Advanced Synthesis (formerly Helsinn Advanced Synthesis)
Dr. Mossi is an experienced leader with a focus on delivering high-quality services and looks forward to taking HAS to the future. He is also member of AITI (Ticino Industrial Association) and Vice President of Farma Industria Ticino (FIT).
Sucheth Davuluri, Neuland Laboratories
Sucheth Davuluri is the Vice- Chairman of the Board and Chief Executive Officer of Neuland Labs, a leading manufacturer of Active Pharmaceuticals for both generic and patented New Chemical Entities. He firmly believes that his role as a leader extends beyond the organisational realm; it’s about inspiring unwavering trust within the team and empowering them to unlock their full potential.
As a member of the founding family, Sucheth’ s overarching vision for Neuland, has been a relentless pursuit of transforming Neuland into one characterised by focusing on quality of business and products that empower progress and enrich lives. Central to this endeavour is the commitment to doing business as a force for good, truly sustainable, and responsible to deliver lasting financial and societal impact.
Sucheth is the Executive member of the YPO, Hyderabad Chapter. He is responsible for working with a highly capable group of CEOs/Heads of companies to improve the overall health, integration, education, and engagement of the chapter.
Sucheth has a degree in Mechanical Engineering and is an alumnus of the University of Notre Dame Mendoza College of Business in Indiana, USA, where he pursued an MBA in corporate finance and operations management. A proficiency in Six Sigma Black Belt, Sucheth leverages operational excellence to strategically expand and fortify Neuland’s presence, operating in a market as rigorously regulated as the aviation industry.
Nelleke Barning, dsm-firmenich
Nelleke Barning, a Dutch national, is global head of sustainability & business solutions at dsm-firmenich’s business unit Health, Nutrition & Care (HNC) since January 2023. She and her team aim to establish HNC as a leader for sustainability in the industry, and secure delivery on the company’s ambitions and targets. The team drives embedding sustainability in the BU strategy and innovation portfolio, with a strong focus on developing solutions with and for customers. Nelleke brings over 20 years’ experience at former DSM in a broad range of communications leadership roles. In the early years of her career, she managed DSM’s first annual sustainability reports, and more recently she played a leading role in the strategic initiative ‘We Make It Possible’, focusing on sustainable animal farming. She lives and works in Basel, Switzerland.
Nicole Schumacher, F. Hoffmann-La Roche Ltd
Nicole Schumacher is Team Lead Compliance and Sustainability in Global Procurement since Fall 2022. In that role, she is responsible to embed Compliance and Sustainability in the procurement and supplier management lifecycle for Pharma (direct and indirect) as well as Diagnostics indirect. With the increasing scope, complexity and impact of our work in the areas of Sustainability and Compliance, a focused capability has been created to emphasise Global Procurements growing responsibilities and value contribution. Prior to that role, Nicole was 9 years Legal Counsel in Roche Group Legal Compliance. In 2017, she was assigned as an interim Head Compliance & Legal in APAC Diagnostics, based in Singapore, for 5 months. Nicole is an Attorney at Law, holding the Master of Law from the University of Basel. She is passionate about traveling and her crazy but lovely 5 year old daughter.
Oliver Viehman, TWS Partners
Oliver Viehman (Principal) leads the Pharma and Life Science Practice Group at TWS Partners. TWS Partners is a strategy consultancy that specializes in leveraging game theory and economic sciences. The purpose of TWS is to bring these powerful, Nobel prize winning frameworks to the real world and create benefit for clients in navigating complex strategic challenges. In the area of sustainability, TWS pioneered a holistic, quantitative approach based on game theory for industry leaders to decarbonize their supply chain. Oliver’s practice group advises global key players in the pharmaceutical industry, both on go-to-market models (with a special focus on commercialization and pricing) and procurement strategies. Oliver studied Philosophy and Physics at LMU Munich and UC Berkeley and holds a PhD in the theory of quantum computing systems.
Pascal Michoux, Teva Pharmaceuticals
Pascal Michoux is the Vice President, Global Head of Environment, Health, Safety and Sustainability, at Teva Pharmaceuticals. He is a Senior EHS&S Executive who has directed a highly talented team of professionals providing Environmental, Health, Safety and Sustainability leadership, and support services for Teva Global Operations including Teva api, Global R&D and Commercial activities for all Teva business units (48 manufacturing sites and distribution centers, with over 37,000 employees in more than 150 locations)
Using his Lean Six Sigma and Opex experience, he spent his last 32 years in EHS&S with companies like MSD and TEVA, defining strategy and coordinating programs to build a safe and sustainable future in complex and changing environments.
Markus Hayek, Kearney
Markus Hayek is a partner in Kearney’s European Health practice. He brings in more than 25 years of consulting and industry experience with a focus on the Health and Life Science industry.
Over more than a decade he has been helping global firms to reshape and transform their supply chain and manufacturing operations and to capture the value from digital and analytics.
Sarah Kerrigan, Kearney
Sarah Kerrigan is the Global Sustainability Director at Kearney. In this role, Sarah works alongside clients to transform and embed sustainability into their end-to-end operations and supply chains. With over 15 years of experience, Sarah specializes in supply chain resilience, traceability, collaboration and partnerships.
Nili Gilbert, Carbon Direct
Nili Gilbert, CFA, CAIA, is the Vice Chairwoman of Carbon Direct, a leader in scaling carbon management into a global industry through climate investment, technology, and client advisory.
She is also Chair of the Glasgow Financial Alliance for Net Zero’s (GFANZ) Advisory Panel of technical experts, as well as a member of its CEO Principals Group. In addition to serving as a Chairwoman of both the David Rockefeller Fund and the Synergos Institute Investment Committees, Nili is an Independent Board Director of Brookfield Asset Management. She is also a Senior Advisor at Boston Consulting Group (BCG) and a member of the Clinton Global Initiative Advisory Council.
Previously, she was Co-Founder and Portfolio Manager of Matarin Capital, which became one of the larger women-owned asset managers in the US. She also previously served as a member of the State of California’s Climate-Related Financial Risk Advisory Group, the Social Mission Board of Seventh Generation, a wholly-owned subsidiary of Unilever, and the TED Vision Council. Her TED Talk on climate finance has received nearly 2 million views.
She has been honored among Barron’s 100 Most Influential Women in U.S. Finance, as a World Economic Forum Young Global Leader, LinkedIn “TopVoice” in Finance, Entrepreneur of the Year by the National Association of Securities Professionals, and Bloomberg BusinessWeek “One to Watch.” She is a permanent member of both the Council on Foreign Relations and the Economic Club of New York.
Nili received her BA, magna cum laude, from Harvard University, her MBA from Columbia Business School, where she was a Toigo Fellow, and she has completed programs in leadership and sustainability at Oxford and Stanford Universities.
Matthew Yamatin, Thermo Fisher Scientific
Matthew Yamativ has served as the Sustainability Program Director at Thermo Fisher Scientific since 2022, where he is responsible for the development and oversight of company-wide environmental sustainability strategy and strategic sustainability customer engagement program. He previously served as the Founder of Decoding Sustainability, a corporate sustainability advisory firm that guided Biogen’s environmental sustainability program including Healthy Climate, Healthy Lives initiative. He holds a Bachelor of Science in Environmental Engineering.
Pierfrancesco Morosini, ICROM srl
Pierfrancesco Morosini has been working in the pharmaceutical sector for 30 years, both in national as well as international settings: half of his career was spent in the R&D function of a pharmaceutical company and the second half in a couple of contract development and manufacturing organisations covering various management roles, from commercial to general management.
Pierfrancesco’s domain expertise is in the pharmaceutical business developments for small molecules as drugs, both for the generic and the branded markets, combined with wide skills in commercial strategy, investments, operations within contract manufacturing organizations.
Since 2015, he is the President and Chief Executive Officer of ICROM srl, an Italian contract development and manufacturing organisation (CDMO), specialized in active pharmaceutical ingredients for human use, covering the full spectrum of company responsibilities with a focus on financials, capital investments and commercial strategy, while being in charge also for all health, safety & environmental responsibilities.
Previous to that, he has worked for another Italian active ingredients CDMO, now called Archimica, with main responsibilities as a business development manager.
At the beginning of his career, Morosini has covered different roles with increasing responsibilities, from lab bench up to the management levels, in the R&D Unit of Bracco SpA, an Italian pharmaceutical company with a global leadership in the field of diagnostic agents, where he served for 13 years. In 1994, during the period at Bracco, he spent 1 year at the University of Texas at Austin within the frame of a research exchange program and in 2000 he has worked for half-a-year at the R&D facility of Bracco Diagnostics in Princeton (NJ, USA) in the field of peptide combinatorial chemistry for pharmaceutical applications.
Pierfrancesco has a Master’s degree in Chemistry with full marks from Pavia University (Italy). He is co-inventor of 8 international patents and co-author in 10 scientific publications in the chemical and pharmaceutical fields.
Pierfrancesco covers the role of member of the Executive Board of ASCHIMFARMA, the Italian association which gathers the manufacturers of pharmaceutical active ingredients.
Nick Hutchinson, Just – Evotec Biologics
Jon Hamer, Curia
Jon Hamer is the Vice President of Global Procurement for Curia Global Inc. Jon joined Curia in September 2019 where he was brought in to build out and develop the Procurement capability of Curia into a World Class Procurement organisation. Prior to Curia, Jon held the position of Senior Director of Procurement for Direct Materials for Abbott Laboratories Inc. He lives in the small market town of Faversham with his wife and two sons and his dog Poppy. His voluntary activities have included amongst other things being a Church Warden for a church dating back to Saxon times and overseeing its sympathetic renovation works. He has performed youth work being a Scout Leader and Sunday School teacher and has a keen interest in the natural world. Most recently he has worked for Natural England, Kent Wildlife and Wildwood Wild Animal Park volunteering and providing wildlife talks as well as monitoring local bee populations. Jon is a keen gardener, enjoys hill walking and renovating clocks.
Christian Hebich, Arcondis Group
Christian Hebich is the CEO of Arcondis Group; he has extensive senior management experience in various focus areas, including corporate strategy, finance, R&D, operations and digital transformation. He holds a master’s degree in finance and business administration from the University of Mannheim, Germany. Christian started his career in 1993 in a management start-up program at the Boehringer Mannheim Group, a company later acquired by Roche. He held many different leadership roles during his 30 years with Roche, covering internal audit, treasury, finance, informatics, general management, operations, engineering and site management. In his previous role at Roche Diagnostics, he led one of the global business areas, focused on the development of complex automation solutions and digital products for professional and PoC laboratories and was part of the global executive leadership team.
Piero Poli, Rivopharm Group
Entrepreneur in the healthcare sector, Piero Poli specializes in generic and equivalent pharmaceutical products, with over 25 years of experience in founding companies and startups. Born in Milan, Italy, Piero has garnered extensive international experience in the pharmaceutical business, working across various countries. In 2005, Piero took the helm of Rivopharm, a company on the brink of bankruptcy, and as CEO, transformed it into an international group headquartered in Switzerland. Under Piero’s leadership, Rivopharm now boasts direct sales in Europe and partnerships in over 50 countries, including the USA and Australia. Piero currently serves as the Chief Executive Officer and President of the Rivopharm Group. Recognized for his remarkable leadership, Piero was honored as the best entrepreneur of the Southern Swiss Regions in 2017 and was a finalist for Swiss Entrepreneur of the Year in 2018. Since 2022 has also proudly served as the President of the Ticino Association of Pharmaceutical Industries (Farma Industria Ticino).”
Samantha Gordine, Arcondis Group
Samantha Gordine is a passionate environmental scientist by training, now working as a sustainability professional in the healthcare sector. She completed her PhD in Marine Biology at the University of St Andrews in 2017 and was shortlisted for a Fulbright scholarship in 2018. Since starting her career, Samantha worked across sectors in academia, the non-profit sector and in the life science industry. Upon moving to Switzerland, she joined the boutique healthcare consulting firm, Arcondis, as a consultant and business developer. She is now establishing and developing Arcondis sustainability solutions portfolio both as a Principal Sustainability Consultant and Sustainability Solution Lead. As part of her current work, Samantha works with major pharmaceutical companies, non-profits, HCOs and other healthcare-related organisations to develop sustainable product lifecycles, make labs more sustainable and drive research for one health outcomes.
Knowing the challenges our world faces, Samantha is driven to help people make the right choices. She is interested in a range of topics such as global health, sustainability, climate change and wildlife crime. Although these topics may seem broad and unrelated, Samantha’s work aims to connect them as elements of the same picture – a healthy planet. This fuels her professional interest in the societal and business-related developments concerning the health of people and the environment.
Stefano Rizzi, Department of Finance and Economics at the Swiss Canton of Ticino
Stefano Rizzi is the Director of the Economics Division at the Department of Finance and Economics. He graduated in Business Economics at the University of St. Gallen, Switzerland, specializing in small and medium enterprises. After his studies he started working in the private sector as an auditor for Ernst & Young and as a social security consultant for SwissLife. Since July 2005 he has worked for the Public Administration of the Swiss Canton of Ticino. He began his career as a consultant for the Department of Economic Development and subsequently worked as a member of the executive team of the Department of Finance and Economics. Since 1 January 2012 he has been head of the Economics Division.
Kamil Tamiola, Peptone
Dr. Kamil Tamiola is a physicist turned entrepreneur. Fascinated by pioneering works of late Prof. Herman Berendsen (University of Groningen in the Netherlands) in the field of molecular dynamics and biomolecular simulations, Kamil decided to pursue an academic career in applied physics and biotechnology.
Yet, it was the bewildering behavior of an exotic class of intrinsically disordered proteins (IDPs) described in seminal works of Prof. Christopher Dobson of Cambridge that brought Kamil’s focus to nuclear magnetic resonance spectroscopy (NMR) and a rapidly emerging field of IDPs.
Besides having a PhD degree in biomolecular sciences and applied physics, Kamil has turned his passion for photography and high altitude mountaineering into a professional activity working as a contributing photographer for National Geographic Benelux, Outdoor Photographer Magazine, Climbing Magazine and shooting commercial campaigns for outdoor brands including Rab, LowePro and others.
Kamil’s free time is split between mountains and grand piano practice, a remnant of his undergraduate piano conservatory education.
Paolo Tubertini, Olon Group
Paolo Tubertini has been the Managing Director of Olon SpA since 2006. From 2003 to 2006 he managed Solmag SpA, with the roles of General Manager and Managing Director, leading the growth and the merger of Solmeg into Olon SpA. He also covered the role of CEO of Antibioticos SpA that was acquired in 2003. He managed the process of unification of commercial and operations between Solmag and Antibioticos.
Paolo Tubertini oversaw acquisition and merging of the many companies of OLON until the creation of the group as it is today. He has been driving new production lines and reorganization of OLON sites, promoting the strong financial stability that has been the base for the development strategy through economic growth and global acquisitions. He oversaw the acquisitions of Infa Group in 2016, of the US Chemical Bioscience Research Division in 2018, of Olon API India in 2019, and more recently of Capua Bioservices SpA.
Paolo Tubertini joint P&R Group in 2003. Previously he dealt with strategic consulting activity as consultant. He studied at Politecnico di Milan and has a degree in Management Engineering.
Luca Sartorello, ICE Pharma
Luca Sartorello is Chief Transformation & Sustainability Officer at ICE Pharma, a position he has held since 2019. In this position he has substantially contributed to building and implementing its growth strategy and governance model, enabling the transformation of a family-owned and run company into a full fledge multinational enterprise. More recently, he has taken the responsibility of defining and implementing the company Sustainability Roadmap.
Prior to his current role, Luca worked at Philip Morris International for six years in Italy and Switzerland, lastly as Global Head of Customer Operations RRP. Previous to that Luca spent six years at McKinsey & Company supporting leading companies in Strategy and Operations.
Luca has an MS Cum Laude in Electronics Engineering from the University of Ferrara, Italy, and gained an MBA from the MIT Sloan School of Management in the US.
Donna Gruol, Lone Fox Endeavors, LLC
Donna J. Gruol has been an active champion of the generic pharmaceutical industry throughout her professional career spanning thirty years. Ms. Gruol’s passion for the pharmaceutical industry is rooted in cultivating highly collaborative relationships that have significantly improved patient outcomes via access to affordable, lifesaving and life-enhancing medicines. She steadfastly believes in the power of an industry network of professionals from all disciplines that outlives one’s current business card or affiliations – and paying it forward.
Ms. Gruol is President and Founder of Lone Fox Endeavors, LLC, a boutique pharmaceutical consulting firm that collaborates with organizations that require expertise in establishing solid strategic business platforms, making essential connections with targeted partners, staff and leadership development, and identifying and utilizing the tools needed to implement, execute and measure performance aligning to the strategic plan.
Ms. Gruol’s work history includes senior and executive leadership positions as Vice President, Business Development for XGen Pharmaceuticals DJB, Inc., Director of Business Development for Xellia Pharmaceuticals APS, and progressive positions over a thirteen-year period gained while at Teva Pharmaceuticals /Teva Parenteral Medicines. Ms. Gruol brings significant enthusiasm to the industry, backed by a broad range of experience to include leading complex projects and alliances from introduction through commercialization, licensing and business development on a global scale, as well as leadership development initiatives, strategic management and organizational framework, and expansion of critical resource integration via improved supply chain management. She enjoys the challenge of taking on complex business challenges and breaking it down into four key tenants – clearly defined and manageable processes, purposeful and prompt communication, cultivating talent and freely sharing experience, best practices and relationships within a vast network.
Ms. Gruol is a graduate of the Graziadio School of Business at Pepperdine, University, earning her Masters of Business Administration in Global Organizational Leadership, and holds a Bachelor of Science in Speech, Language Pathology from Marquette University, among other academic pursuits. She currently serves as First Vice President of the DCAT Board of Directors. Previously, she served on DCAT’s Leadership Development Committee, Advisory Council, Alliance for Industry Women Committee, and former Committee Chair of the Membership Advantage Committee.
Kelsey Achenbach, dsm-firmenich
Kelsey Achenbach has been serving the pharmaceutical and specialty chemical industries for more than 20 years, and has a strong passion for improving the lives of patients through partnerships and innovation. Ms. Achenbach has experience in operations management, business development, commercial management, and strategic business transformation. Currently, Ms. Achenbach leads the Global Pharmaceutical and Global Medical Nutrition businesses at dsm-firmenich; leading innovation and development of critical ingredients in parenteral and enteral nutrition while focusing on improving patient access to critical medications. Before joining dsm-firmenich, Ms. Achenbach had extensive experience in supplying and partnering with the pharmaceutical industry; holding strategic leadership roles at Roquette, Celanese, and FMC.
Ms. Achenbach currently serves as Second Vice President of the DCAT organization. Prior to joining the DCAT Board of Directors, Ms. Achenbach was an active volunteer and advocate for the DCAT organization; holding positions on the Advisory Board and several committees over the past 7 years. Most recently, Ms. Achenbach chaired the Membership Advantage Committee.
In addition to her continued education and certifications in business leadership, Ms. Achenbach holds a B.S. in Chemical Engineering from the University of Minnesota and MBAs from Columbia Business School and London Business School.
Paolo Magri, Bioseutica
Paolo Magrì is CEO of the Bioseutica Group, active in the production of pharma grade natural proteins and enzymes. The Group is headquartered in The Netherlands, with offices in Switzerland and production sites in British Columbia (CA). Mr. Magrì has over 30 years of experience in the active pharmaceutical ingredient (API) industry. Prior to joining Bioseutica, he served as senior VP at Advitech Advisory and Technologies. Previous to that role, he served as Vice President of corporate business development at Infa Group, and as marketing and sales Director at Sicor and in Teva’s API division, after the acquisition of Sicor by Teva in 2004.
Mr. Magrì previously served on DCAT’s Board of Directors from 2016-2022. His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras. Mr. Magrì earned his Master’s degree in chemistry and pharmaceutical technology from the University of Milan, Italy.
Luca Dalla Torre, Siegfried
Luca Dalla Torre joined Siegfried in 2012 as General Counsel and Secretary to the Board of Directors. Since 2021, he holds the additional responsibility of Chairman of the Sustainability Board of Siegfried. This role involves defining the sustainability strategy and implementing the sustainability program on a global level, as well as overseeing ESG target setting and progress reporting in a GRI compliant manner.
Prior to joining Siegfried, he held senior positions with corporate law firms in Zurich and New York, with a focus on mergers and acquisitions. He is a member of the Board of Scienceindustries, the Swiss Business Association Chemistry Pharma Life Sciences, and the Aargau Chamber of Industry and Commerce.
Luca holds a Ph.D. in law and a Bachelor of economics from the University of Bern. He also holds an LL.M. in corporate law from New York University and is completing a Professional Certificate in sustainability from MIT. He is a Swiss citizen.
